ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
MammaPrint® Approved for Reimbursement in Germany
IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today that the Federal Joint Committee (G-BA) has approved MammaPrint® , Agendia's 70-Gene Breast Cancer Recurrence Assay. The G-BA Read More
Agendia to Participate in Stifel 2020 Virtual Healthcare Conference
Irvine, Calif., October 15, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Read More
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
IRVINE, CALIF., U.S – 6 October 2020 – Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Read More
Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation
I AM HERE: An Intimate Portrait Series launches today Irvine, Calif., October 1, 2020 – In celebration of Breast Cancer Awareness Month, Agendia, Inc., a world leader in precision oncology for breast cancer, is proud Read More